Company Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders.
The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.
The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders.
GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Country | IE |
IPO Date | Jun 25, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 49 |
CEO | Dr. Velichka Valcheva M.D. |
Contact Details
Address: 28 Baggot Street Lower Dublin, IE | |
Website | https://www.ghres.com |
Stock Details
Ticker Symbol | GHRS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001855129 |
CUSIP Number | G3855L106 |
ISIN Number | IE000GID8VI0 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Velichka Valcheva M.D. | Chief Executive Officer |
Aaron Cameron M.B.A. | Chief Operating Officer |
Florian Schonharting M.Sc. (Econ) | Co-Founder & Non-Executive Chairman of the Board |
Julie Ryan F.C.A. | Vice President of Finance |
Magnus Halle | Co-Founder & MD of Ireland |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 05, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | 6-K | Filing |
Sep 20, 2024 | 6-K | Filing |
Sep 16, 2024 | 6-K | Filing |
Sep 09, 2024 | 6-K | Filing |
Sep 03, 2024 | 6-K | Filing |
Sep 03, 2024 | 6-K | Filing |
Sep 03, 2024 | 6-K | Filing |